Skip to main content

EvoEndo® Surpasses 3,000 Sedation-Free Transnasal Endoscopy Procedures Nationwide

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

EvoEndo®, Inc. (EvoEndo) today announced that practitioners have now completed more than 3,000 sedation-free transnasal endoscopy (TNE) procedures using the EvoEndo Endoscopy System, as implementation expands to more than 70 locations nationwide.

“Reaching 3,000 cases is an important milestone, but what matters most is what it represents for patients, families, and physicians,” said Jonathan Hartmann, CEO of EvoEndo. “Every case reflects greater access to sedation-free endoscopy and the trust our partners place in EvoEndo.”

EvoEndo's footprint now extends from Boston to San Francisco, including sites in Philadelphia, Cleveland, Milwaukee, Birmingham, and Orlando. At Phoenix Children's Hospital, an early adopter, practitioners have completed more than 300 procedures.

More than 100 practitioners have adopted the EvoEndo Endoscopy System. “We have been thrilled to offer our patients a less invasive option for managing and monitoring their eosinophilic esophagitis,” said Dr. Eitan Rubinstein, Assistant Professor in Pediatrics at Harvard Medical School and Attending Physician in the Department of Gastroenterology and Nutrition at Boston Children’s Hospital.

Dr. Aravind Thavamani, Pediatric Gastroenterologist at University Hospitals Rainbow Babies & Children’s Hospital, said, “TNE has changed the way I approach endoscopy in my pediatric patients — no sedation, no recovery room, and a child who walks out the door minutes after the procedure. EvoEndo’s platform gives me the tools to make that a reality with enhanced diagnostic capability.”

EvoEndo continues to expand access to sedation-free endoscopy across hospitals, clinics, and satellite locations nationwide. Patients and families can learn more at evoendopatient.com, and physicians interested in the EvoEndo Endoscopy System can request information at evoendo.com.

About EvoEndo

EvoEndo, Inc. is a medical device company developing systems that enable sedation-free endoscopic procedures with sterile single-use, flexible endoscopes for both adult and pediatric patients.

The EvoEndo® Model LE Gastroscope is intended for the visualization of the upper digestive tract in adults and pediatric patients, specifically for the observation, diagnosis, and endoscopic treatment of the esophagus, stomach, and duodenal bulb. The gastroscope is a sterile single-use device and can be inserted orally or transnasally. The 110 cm gastroscope is intended to be used in adult and pediatric populations. The 85 cm gastroscope is intended to be used in the pediatric population. The EvoEndo Controller is intended for use with an EvoEndo Endoscope for endoscopic diagnosis, treatment, and video observation.

© 2026 EvoEndo, Inc. US: Rx only. For use by trained physicians only.

“TNE has changed the way I approach endoscopy in my pediatric patients — no sedation, no recovery room, and a child who walks out the door minutes after the procedure.” — Dr. Aravind Thavamani, University Hospitals Rainbow Babies & Children’s Hospital

Contacts

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  232.11
-1.55 (-0.66%)
AAPL  333.02
+11.36 (3.53%)
AMD  521.95
-17.74 (-3.29%)
BAC  62.05
+0.77 (1.26%)
GOOG  319.09
+0.75 (0.24%)
META  595.19
-10.91 (-1.80%)
MSFT  381.70
+0.12 (0.03%)
NVDA  206.84
-1.92 (-0.92%)
ORCL  114.99
-5.05 (-4.21%)
TSLA  313.03
-6.66 (-2.08%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.